company background image
VLA logo

Valneva ENXTPA:VLA Stock Report

Last Price

€3.60

Market Cap

€500.7m

7D

8.6%

1Y

-42.7%

Updated

20 Aug, 2024

Data

Company Financials +

Valneva SE

ENXTPA:VLA Stock Report

Market Cap: €500.7m

VLA Stock Overview

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

About the company

VLA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Earnings are forecast to grow 28.34% per year

Risk Analysis

Has less than 1 year of cash runway
Volatile share price over the past 3 months

Valneva SE Competitors

Eurobio Scientific Société anonyme

ENXTPA:ALERS

€247.1m

Genfit

ENXTPA:GNFT

€194.2m

Innate Pharma

ENXTPA:IPH

€166.8m

Transgene

ENXTPA:TNG

€134.6m

Price History & Performance

Summary of all time highs, changes and price drops for Valneva
Historical stock prices
Current Share Price€3.60
52 Week High€7.17
52 Week Low€2.93
Beta0.97
11 Month Change9.83%
3 Month Change-10.27%
1 Year Change-42.69%
33 Year Change-73.39%
5 Year Change16.25%
Change since IPO-67.17%

Recent News & Updates

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17
Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17
Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10
Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05
Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27
Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15
Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06
News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Dec 13
Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Aug 10
Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

May 12
Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Jan 30
Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Is Valneva (EPA:VLA) Using Debt Sensibly?

Sep 18
Is Valneva (EPA:VLA) Using Debt Sensibly?

Shareholder Returns

VLAFR BiotechsFR Market
7D8.6%3.4%3.0%
1Y-42.7%-24.7%0.3%

Return vs Industry: VLA underperformed the French Biotechs industry which returned -23.1% over the past year.

Return vs Market: VLA underperformed the French Market which returned 1% over the past year.

Price Volatility

Is VLA's price volatile compared to industry and market?
VLA volatility
VLA Average Weekly Movement8.4%
Biotechs Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market2.6%

Stable Share Price: VLA has not had significant price volatility in the past 3 months.

Volatility Over Time: VLA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
1998700Thomas Lingelbachvalneva.com

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

Valneva SE Fundamentals Summary

How do Valneva's earnings and revenue compare to its market cap?
VLA fundamental statistics
Market cap€500.67m
Earnings (TTM)-€32.41m
Revenue (TTM)€156.47m

3.2x

P/S Ratio

-15.4x

P/E Ratio

Is VLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VLA income statement (TTM)
Revenue€156.47m
Cost of Revenue€156.26m
Gross Profit€209.00k
Other Expenses€32.62m
Earnings-€32.41m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)-0.23
Gross Margin0.13%
Net Profit Margin-20.71%
Debt/Equity Ratio108.5%

How did VLA perform over the long term?

See historical performance and comparison